© 2001 by European Society of Cardiology
Copyright © 2001, European Society of Cardiology
Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards
Cardiovascular Research Institute of the MedStar Research Institute, Washington Hospital Center, Washington, DC, USA
* Corresponding author. Tel.: +1-202-877-5977; fax: +1-202-877-3339 sxe2{at}mhg.edu
The importance of spontaneously developing collateral vessels to supplement perfusion of tissue rendered ischemic by vascular obstruction was recognized many years ago. However, it was not until potent angiogenesis factors were identified, purified, and produced in sufficient quantities, that the field began its rapid development. In the early 1990s it was first shown that basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) proteins could actually stimulate collateral flow. However, additional studies also demonstrated that the duration of exposure of the vessels to angiogenesis factors was critical, and that the administration of proteins, with their relativly brief half-lives, may pose important practical limitations. The demonstration that gene therapy can improve collateral function presents one of the solutions to the conundrum, since gene therapy can be considered a sophisticated form of a sustained delivery system. The results of several clinical trials have been reported. All involve administration of single angiogenesis agents, and most are Phase I trials. The two studies rising to Phase II status demonstrated no treatment effect on the primary end-point. It may therefore be relevant to consider that the molecular mechanisms responsible for angiogenesis are extraordinarily complex, and an optimal angiogenesis intervention may require a ‘multiple factor’ strategy. It is important to note that no serious side-effects ascribable to an angiogenesis agent were recognized in these trials. However, angiogenesis agents are potent molecules with multiple activities. It is therefore possible that they might occasionally cause side-effects, some serious. Among these, based on their biologic activities, are neovascularization of non-targeted tissues, expansion and induction of instability of atherogenic plaque, and growth of tumors. In summary, there is ample experimental evidence justifying an optimistic outlook relating to our eventually being successful in enhancing collateral flow to ischemic tissue in a clinical setting. However, we are not there yet, and identification of the optimal angiogenesis strategy is still unclear. Additional experimental work, in parallel with large, carefully controlled clinical trials are needed to continue the exciting advances of the last decade, and to achieve the goal of providing patients with alternative potent therapies to improve collateral flow, and thereby to alleviate their symptoms and perhaps to prolong their lives.
KEYWORDS Angiogenesis; Collateral circulation; Coronory circulation; Growth factors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Onimaru, Y. Yonemitsu, T. Fujii, M. Tanii, T. Nakano, K. Nakagawa, R.-i. Kohno, M. Hasegawa, S.-i. Nishikawa, and K. Sueishi VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1685 - H1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Seko, N. Nitta, A. Sonoda, S. Ohta, M. Takahashi, K. Murata, and Y. Tabata Vascular Regeneration by Repeated Infusions of Basic Fibroblast Growth Factor in a Rabbit Model of Hind-Limb Ischemia Am. J. Roentgenol., June 1, 2009; 192(6): W306 - W310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lee, H. J. Chung, and T. G. Park Perspectives On: Local and Sustained Delivery of Angiogenic Growth Factors Journal of Bioactive and Compatible Polymers, January 1, 2007; 22(1): 89 - 114. [Abstract] [PDF]
|
|
|
|
|
|
K. Kaneko, Y. Yonemitsu, T. Fujii, M. Onimaru, C.-H. Jin, M. Inoue, M. Hasegawa, T. Onohara, Y. Maehara, and K. Sueishi A free radical scavenger but not FGF-2-mediated angiogenic therapy rescues myonephropathic metabolic syndrome in severe hindlimb ischemia Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1484 - H1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanii, Y. Yonemitsu, T. Fujii, Y. Shikada, R.-i. Kohno, M. Onimaru, S. Okano, M. Inoue, M. Hasegawa, T. Onohara, et al. Diabetic Microangiopathy in Ischemic Limb Is a Disease of Disturbance of the Platelet-Derived Growth Factor-BB/Protein Kinase C Axis but Not of Impaired Expression of Angiogenic Factors Circ. Res., January 6, 2006; 98(1): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Geer, D. D. Swartz, and S. T. Andreadis Biomimetic Delivery of Keratinocyte Growth Factor upon Cellular Demand for Accelerated Wound Healing in Vitro and in Vivo Am. J. Pathol., December 1, 2005; 167(6): 1575 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath, C. Y. J. Lu, E. Robert, G. F. Pierce, R. Greene, B. A. Sosnowski, and J. Doukas Improvement of myocardial contractility in a porcine model of chronic ischemia using a combined transmyocardial revascularization and gene therapy approach J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Li, K. Tanaka, A. Ihaya, Y. Fujibayashi, S. Takamatsu, K. Morioka, M. Sasaki, T. Uesaka, T. Kimura, N. Yamada, et al. Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H408 - H415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hosaka, H. Koyama, T. Kushibiki, Y. Tabata, N. Nishiyama, T. Miyata, H. Shigematsu, T. Takato, and H. Nagawa Gelatin Hydrogel Microspheres Enable Pinpoint Delivery of Basic Fibroblast Growth Factor for the Development of Functional Collateral Vessels Circulation, November 23, 2004; 110(21): 3322 - 3328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Heil and W. Schaper Influence of Mechanical, Cellular, and Molecular Factors on Collateral Artery Growth (Arteriogenesis) Circ. Res., September 3, 2004; 95(5): 449 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kinnaird, E. Stabile, M. S. Burnett, and S. E. Epstein Bone Marrow-Derived Cells for Enhancing Collateral Development: Mechanisms, Animal Data, and Initial Clinical Experiences Circ. Res., August 20, 2004; 95(4): 354 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hattan, D. Warltier, W. Gu, C. Kolz, W. M. Chilian, and D. Weihrauch Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H488 - H493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Unthank, K. M. Sheridan, and M. C. Dalsing Collateral Growth in the Peripheral Circulation: A Review Vascular and Endovascular Surgery, July 1, 2004; 38(4): 291 - 313. [Abstract] [PDF]
|
|
|
|
|
|
T. Kinnaird, E. Stabile, M.S. Burnett, C.W. Lee, S. Barr, S. Fuchs, and S.E. Epstein Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms Circ. Res., March 19, 2004; 94(5): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Attmann, C. Heilmann, M. Siepe, J. Martin, F. Jentzmik, P. von Samson, F. Beyersdorf, and G. Lutter Transgenic and transmural revascularization: regional myocardial tissue pressure during chronic ischemia Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 138 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shoji, Y. Yonemitsu, K. Komori, M. Tanii, H. Itoh, S. Sata, H. Shimokawa, M. Hasegawa, K. Sueishi, and Y. Maehara Intramuscular gene transfer of FGF-2 attenuates endothelial dysfunction and inhibits intimal hyperplasia of vein grafts in poor-runoff limbs of rabbit Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H173 - H182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Schwartz and R Kornowski Progenitor and embryonic stem cell transplantation for myocardial angiogenesis and functional restoration Eur. Heart J., March 1, 2003; 24(5): 404 - 411. [Full Text] [PDF]
|
|
|
|
|
|
B. E. Strauer and R. Kornowski Stem Cell Therapy in Perspective Circulation, February 25, 2003; 107(7): 929 - 934. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Baatar, M. K. Jones, K. Tsugawa, R. Pai, W. S. Moon, G. Y. Koh, I. Kim, S. Kitano, and A. S. Tarnawski Esophageal Ulceration Triggers Expression of Hypoxia-Inducible Factor-1{alpha} and Activates Vascular Endothelial Growth Factor Gene : Implications for Angiogenesis and Ulcer Healing Am. J. Pathol., October 1, 2002; 161(4): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath, J. Doukas, C.-Y. J. Lu, N. Belkind, R. Greene, G. F. Pierce, and D. A. Fullerton Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging Ann. Thorac. Surg., August 1, 2002; 74(2): 481 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yokoyama and T. Hirase Harmonic Interplay of Angiogenic Growth Factors in the Development of Coronary Blood Vessels Circ. Res., June 8, 2001; 88(11): 1099 - 1101. [Full Text] [PDF]
|
|